Tags : Forty Seven

PharmaShots Weekly Snapshot (March 02-06, 2020)

1. Mount Sinai Signs a Multi-Year Collaboration with Harbour BioMed to Develop Novel Biotherapies for Multiple Cancer Indications and COVID-19 Published: Mar 06, 2020 | Tags: Mount Sinai, Signs, Multi-Year, Collaboration, Harbour BioMed, Develop, Novel Biotherapies, Multiple Cancer Indications, COVID-19 2. AstraZeneca Reports Results of Imfinzi and Tremelimumab in P-III DANUBE Study for Unresectable Stage IV […]Read More

Gilead to Acquire Forty Seven for $4.9B

Shots: Gilead to acquire Forty Seven in an all-cash transaction for $95.50/share, making a total deal value of ~$4.9B. The transaction is anticipated to be closed in Q2’20 The focus of the acquisition is to bolster Gilead’s immune-oncology portfolio with the addition of Forty Seven’s magrolimab which complements its existing work in hematology and two […]Read More

PharmaShots Weekly Snapshot (November 11-15, 2019)

Roche’s Kadcyla (trastuzumab emtansine) Receives CHMP’s Recommendation for Approval as an Adjuvant Treatment for Patients with HER2+ eBC with Residual Invasive Disease After Neoadjuvant Treatment Published: Nov 15, 2019 | Tags: Roche, Kadcyla, trastuzumab emtansine, Receives, CHMP, Recommendation, Approval, Adjuvant, Treatment, HER2+ Early Breast Cancer 2. Stanford Medicine Reports Results of Apple Heart Study for Detecting […]Read More

Bluebird Bio Collaborates with Forty Seven to Evaluate Antibody Conditioning

Shots: The collaboration will lead to evaluation of Forty Seven’s FSI-174 + magrolimab in combination with Bluebird’s ex vivo lentiviral vector hematopoietic stem cell (LVV HSC) gene therapy platform The focus of the collaboration is to develop gene therapy with reduced toxicity and will initially target diseases having the potential to be corrected with transplantation […]Read More